title: Hemostatic studies in racing standardbred horses with exercise-induced pulmonary hemorrhage. Hemostatic parameters at rest and after moderate exercise.
abstract: The purpose of this study was to determine whether a defect in hemostasis might be a factor in the etiology of exercise-induced pulmonary hemorrhage (EIPH). Hemostatic parameters were evaluated in 22 EIPH-positive and ten EIPH-negative racing horses while in a rested state. Nineteen EIPH-positive and ten EIPH-negative horses were further evaluated just before and immediately after a 15 min exercise period on a 260 m oval track. When EIPH-positive and EIPH-negative horses were compared at rest, there was no significant difference in any of the coagulation and fibrinolytic parameters studied. There was however, a significant difference in platelet function as assessed by aggregometry. The platelets from affected horses were significantly less responsive than those from nonaffected horses when exposed in vitro to the platelet agonists adenosine diphosphate, collagen and platelet activating factor. Exercise tended to increase the packed cell volume and factor VIII/von Willebrand factor and to decrease platelet aggregation responses to low concentrations of adenosine diphosphate. These effects of exercise however were quantitatively similar in both EIPH-positive and EIPH-negative horses. Reduced platelet function may therefore be a contributing factor in the bleeding characteristic of horses with EIPH.
authors.affiliation: Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Ontario.
authors.forename: I B
authors.initials: IB
authors.lastname: Johnstone
authors.forename: L
authors.initials: L
authors.lastname: Viel
authors.forename: S
authors.initials: S
authors.lastname: Crane
authors.forename: T
authors.initials: T
authors.lastname: Whiting
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D000990:Antithrombin III / Q000032:analysis; D003094:Collagen / Q000494:pharmacology; D005169:Factor VIII / Q000032:analysis; D005337:Fibrin / Q000032:analysis; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006400:Hematocrit / Q000662:veterinary; D006470:Hemorrhage / Q000097:blood / Q000209:etiology / Q000662:veterinary*; D006487:Hemostasis; D006734:Horse Diseases / Q000097:blood* / Q000209:etiology; D006736:Horses; D008171:Lung Diseases / Q000097:blood / Q000209:etiology / Q000662:veterinary*; D010314:Partial Thromboplastin Time / Q000662:veterinary; D005082:Physical Exertion; D010972:Platelet Activating Factor / Q000494:pharmacology; D010974:Platelet Aggregation; D010976:Platelet Count / Q000662:veterinary; D011517:Prothrombin Time / Q000662:veterinary; D013918:Thrombin Time / Q000662:veterinary; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D010972:Platelet Activating Factor; D014841:von Willebrand Factor; D000244:Adenosine Diphosphate; D000990:Antithrombin III; D005169:Factor VIII; D005337:Fibrin; D005340:Fibrinogen; D003094:Collagen